Polysaccharide A - Symbiotix Biotherapies

Drug Profile

Polysaccharide A - Symbiotix Biotherapies

Alternative Names: PSA - Symbiotix Biotherapies; Reglemers™; SYMB 104; ZPS therapeutic - Symbiotix; Zwitterionic polysaccharide - Symbiotix

Latest Information Update: 26 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Symbiotix Biotherapies
  • Developer Geisel School of Medicine; Symbiotix Biotherapies
  • Class Antibacterials; Polysaccharides
  • Mechanism of Action CD4-positive T-lymphocyte modulators; Immunomodulators; Interleukin-10 expression stimulants; Regulatory T-lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Inflammatory bowel diseases; Multiple sclerosis

Most Recent Events

  • 21 Mar 2018 Symbiotix Biotherapies in-licenses intellectual property from Harvard University
  • 03 Jan 2018 Symbiotix Biotherapies and Paragon Bioservices agree for process development and to manufacture polysaccharide A (SYMB 104)
  • 03 Jan 2018 Symbiotix Biotherapies plans a clinical trials for immune-mediated diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top